• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病关节炎:当前主题

Psoriatic arthritis: current topics.

作者信息

McCarey David, McInnes Iain B

机构信息

Centre for Rheumatic Diseases, University of Glasgow, 10 Alexandra Parade, Glasgow, Scotland, G31 2ER, UK.

出版信息

Curr Rheumatol Rep. 2007 Dec;9(6):442-8. doi: 10.1007/s11926-007-0072-4.

DOI:10.1007/s11926-007-0072-4
PMID:18177596
Abstract

Psoriatic arthritis is a common inflammatory arthropathy that occurs in approximately 25% of psoriasis patients. Due to significant advances in therapeutics--mainly the advent of biologic therapy--the disease has been subject to intense investigation recently. This review summarizes recent investigations of disease pathogenesis and clinical treatment. Clinical responses to tumor necrosis factor-blocking agents appear robust and superior to traditional disease-modifying drug responses, whereas other interventions, such as costimulation blockade, require more investigation. The pathogenesis of the disease appears related to T helper 17-polarized immune responses that target skin, joints, and the enthesial compartment. Finally, new insights into the disorder's genetic antecedents are emerging as more cohorts of patients undergo advanced genetic screening methods.

摘要

银屑病关节炎是一种常见的炎性关节病,约25%的银屑病患者会出现该病症。由于治疗方法取得了重大进展——主要是生物疗法的出现——近年来对该疾病的研究十分深入。这篇综述总结了近期关于疾病发病机制和临床治疗的研究。对肿瘤坏死因子阻断剂的临床反应似乎很显著,且优于传统的改善病情药物的反应,而其他干预措施,如共刺激阻断,还需要更多研究。该疾病的发病机制似乎与以皮肤、关节和肌腱附着点为靶点的辅助性T细胞17极化免疫反应有关。最后,随着越来越多的患者群体接受先进的基因筛查方法,对该疾病遗传病因的新见解正在不断涌现。

相似文献

1
Psoriatic arthritis: current topics.银屑病关节炎:当前主题
Curr Rheumatol Rep. 2007 Dec;9(6):442-8. doi: 10.1007/s11926-007-0072-4.
2
Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.生物制剂和其他疾病修正抗风湿药物对银屑病和银屑病关节炎患者心血管结局的影响:系统评价。
Curr Pharm Des. 2014;20(4):500-12. doi: 10.2174/138161282004140213123505.
3
Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options.银屑病关节炎:针对发病机制的治疗选择的当前概念
Arthritis Rheum. 2007 Apr;56(4):1051-66. doi: 10.1002/art.22489.
4
Psoriatic arthritis: current therapy and future approaches.银屑病关节炎:当前的治疗方法和未来的方法。
Rheumatology (Oxford). 2015 Jan;54(1):20-8. doi: 10.1093/rheumatology/keu237. Epub 2014 Aug 14.
5
Psoriatic arthritis treatment: biological response modifiers.银屑病关节炎的治疗:生物反应调节剂
Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii78-82. doi: 10.1136/ard.2004.034157.
6
Recent advances in the management of psoriatic arthritis.银屑病关节炎治疗的最新进展
Curr Opin Rheumatol. 2004 Jul;16(4):366-70. doi: 10.1097/01.bor.0000129720.21563.b8.
7
Psoriatic arthritis therapy advances.银屑病关节炎治疗取得进展。
Curr Opin Rheumatol. 2005 Jul;17(4):426-32. doi: 10.1097/01.bor.0000166382.96024.85.
8
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.肿瘤坏死因子α抑制剂在银屑病和银屑病关节炎治疗中的应用
BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006.
9
An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.生物制剂类改善病情抗风湿药治疗中轴型脊柱关节炎和银屑病关节炎的概述。
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):453-471. doi: 10.1016/j.berh.2018.12.002. Epub 2019 Mar 21.
10
Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.内皮功能障碍及 TNF 抑制剂对银屑病和银屑病关节炎患者内皮细胞的影响:系统评价。
Curr Pharm Des. 2014;20(4):513-28. doi: 10.2174/138161282004140213123852.

引用本文的文献

1
Update on the treatment of peripheral arthritis in psoriatic arthritis.银屑病关节炎外周关节炎治疗的最新进展
Curr Rheumatol Rep. 2009 Aug;11(4):270-7. doi: 10.1007/s11926-009-0038-9.
2
Treatment recommendations for psoriatic arthritis.银屑病关节炎的治疗建议。
Ann Rheum Dis. 2009 Sep;68(9):1387-94. doi: 10.1136/ard.2008.094946. Epub 2008 Oct 24.

本文引用的文献

1
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.在无临床明显心血管疾病或经典动脉粥样硬化危险因素的银屑病关节炎患者中,亚临床动脉粥样硬化的患病率较高。
Arthritis Rheum. 2007 Aug 15;57(6):1074-80. doi: 10.1002/art.22884.
2
Improved survival in psoriatic arthritis with calendar time.银屑病关节炎患者随日历时间推移生存率提高。
Arthritis Rheum. 2007 Aug;56(8):2708-14. doi: 10.1002/art.22800.
3
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
英夫利昔单抗在一年的治疗中可抑制活动性银屑病关节炎患者影像学损伤的进展:诱导和维持性银屑病关节炎临床试验2的结果
Arthritis Rheum. 2007 Aug;56(8):2698-707. doi: 10.1002/art.22805.
4
TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele.银屑病中的肿瘤坏死因子多态性:银屑病关节炎与启动子多态性TNF*-857的关联,独立于PSORS1风险等位基因。
Arthritis Rheum. 2007 Jun;56(6):2056-64. doi: 10.1002/art.22590.
5
Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.无临床明显心血管疾病或经典动脉粥样硬化危险因素的银屑病关节炎患者的内皮功能障碍。
Arthritis Rheum. 2007 Mar 15;57(2):287-93. doi: 10.1002/art.22530.
6
Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study.肿瘤坏死因子阻断剂对银屑病关节炎患者心血管危险因素的影响:一项双盲、安慰剂对照研究。
Arthritis Rheum. 2007 Mar;56(3):831-9. doi: 10.1002/art.22447.
7
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.一种用于治疗银屑病的人白细胞介素-12/23单克隆抗体。
N Engl J Med. 2007 Feb 8;356(6):580-92. doi: 10.1056/NEJMoa062382.
8
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.白细胞介素-20亚家族细胞因子对重组人表皮的影响表明其在银屑病皮肤固有防御和致病性适应性免疫中具有潜在作用。
J Immunol. 2007 Feb 15;178(4):2229-40. doi: 10.4049/jimmunol.178.4.2229.
9
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.阿达木单抗用于银屑病关节炎的长期治疗:来自阿达木单抗治疗银屑病关节炎有效性试验的48周数据。
Arthritis Rheum. 2007 Feb;56(2):476-88. doi: 10.1002/art.22379.
10
HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.HLA - Cw6和HLA - DRB1*07共同与银屑病关节炎中较轻的关节疾病相关。
Ann Rheum Dis. 2007 Jun;66(6):807-11. doi: 10.1136/ard.2006.064972. Epub 2007 Jan 12.